Developer docs
API playgroundTry for free, no card

Search company profiles

Mabqi

Full company profile

uuid00036yg

Namestring
Mabqi
Legal namestring
MABQI S.A.S.
Websiteurl
mabqi.com
Company typeenum
Private
Founded yearint
2017
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGrabels, France
HQ citystring
Grabels
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody discovery services, therapeutic antibody development, phage display technology, oncology biopharmaceuticals, antibody drug conjugates
Industry3 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Pharmaceutical Preparation Manufacturing325412
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical R&D Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Partnership and Collaborative Research Agreements
TypeProfessional Services
Description

Mabqi generates revenue through fee-for-service discovery partnerships with biopharma companies, where it applies its LiteMab platform to discover antibodies against targets defined by partners. Revenue is earned at project milestones (hit identification, lead selection, IND-enabling studies).

mabqi.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

The company earns licensing revenue and milestone payments when partnered antibody programs advance through development and regulatory stages. The Syndivia ADC licensing agreement (January 2026) exemplifies this model, where an option on a jointly discovered ADC was exercised by a pharma company, generating licensing income.

mabqi.com
3Non-Dilutive Public Funding
TypeManaged Services
Description

Mabqi supplements its operations through non-dilutive public funding grants, notably the €5 million France 2030 award in 2025 to advance lead candidate MQI-201. This supports preclinical development and IND-enabling studies without equity dilution.

mabqi.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom project-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

No publicly listed pricing tiers. All engagements are custom quotes based on project scope, target complexity, and deliverable requirements. Potential partners contact Mabqi directly for proposals.

mabqi.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Mabqi is a biopharmaceutical company that discovers and develops next-generation therapeutic antibodies and immunotherapies, primarily in oncology. The company operates the LiteMab© Antibody Discovery Studio, an integrated platform combining proprietary fully human synthetic antibody libraries (HuscI2 and pHuscI2) with AI-powered phage and yeast display technologies to deliver developable therapeutic antibody candidates in approximately 4 months. Mabqi offers fee-for-service discovery partnerships, co-development collaborations, and licensing arrangements to biopharma clients, and is also advancing a proprietary pipeline including MQI-201 and MQI-181.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 4-month timeline from target to validated lead
+3 more records
Product overview1 text field

Mabqi offers a unified antibody discovery ecosystem centered on the LiteMab© Antibody Discovery Studio, which integrates three core platforms: LiteMab© for conventional fully human antibody discovery from proprietary synthetic libraries; LiteMab© Sense for conditionally active pH-sensitive tumor-selective antibodies; and LiteMab© Neo for affinity maturation and LiteMab© Neo Sense for pH-sensitive maturation. The company leverages AI-powered phage and yeast display technologies to deliver readily developable therapeutic candidates across formats including conventional mAbs, bispecifics/multispecifics, T-cell engagers (TCEs), and antibody-drug conjugates (ADCs). Mabqi's proprietary pipeline includes MQI-201 (first-in-class anti-TRPV6 antibody for solid tumors, entering clinical development) and MQI-181 (pH-sensitive ADC for hemato-oncology), alongside multiple discovery-stage programs. Services include antibody characterization, developability assessment, and functional validation through internalization and cytotoxicity assays.

Product and service8 records
1LiteMab© Antibody Discovery Studio
CategoryAntibody Discovery Platform
Description

Comprehensive integrated antibody discovery platform combining proprietary fully human synthetic libraries with AI-powered phage and yeast display technologies for high-throughput selection, screening, and functional validation of therapeutic antibody candidates. Supports conventional mAbs, bispecifics, multispecifics, T-cell engagers, pH-sensitive antibodies, and ADCs.

2LiteMab© (Core Antibody Discovery)
CategoryAntibody Discovery Service
Description

Core antibody discovery offering powered by proprietary high-diversity fully human synthetic antibody libraries spanning broad structural and paratope landscapes. Enables discovery of conventional antibodies including against complex and difficult targets such as GPCRs and ion channels.

3LiteMab© Sense (pH-Sensitive Antibodies)
CategoryAntibody Discovery Service
Description

Conditionally active pH-sensitive antibody discovery offering leveraging a proprietary fully human synthetic pH-sensitive naive library (pHuscI2). Generates tumor-selective antibodies that preferentially bind in the acidic tumor microenvironment while showing reduced binding at physiological pH, enhancing specificity and reducing off-tumor toxicity.

4LiteMab© Neo (Affinity Maturation)
CategoryAntibody Maturation Service
Description

Affinity maturation platform for next-generation biologics. Provides customized library design based on parental sequences with AI-powered dual display technology enabling precise tuning of affinity, pH sensitivity, and functional activity while preserving developability.

5Antibody Drug Conjugate (ADC) Discovery
CategoryAntibody Discovery Service
Description

ADC discovery service combining targeting specificity of monoclonal antibodies with potent cytotoxicity of chemotherapeutic agents. Supports generation of native or pH-sensitive antibodies using AI-powered dual display for rapid clone identification, hit characterization, and functional validation including internalization assays and cytotoxicity testing.

6Bispecific & Multispecific Antibody Discovery
CategoryAntibody Discovery Service
Description

Discovery service delivering high-affinity binders tailored for complex bispecific, multispecific, and T-cell engager (TCE) formats. Leverages AI-powered dual-display workflows and synthetic libraries with scFv format enabling rapid assembly and flexible combination of binding domains.

7MQI-201 (Anti-TRPV6 Antibody Candidate)
CategoryProprietary Clinical Candidate
Description

First-in-class anti-TRPV6 antibody therapeutic candidate for solid tumors. Demonstrated safety and efficacy in metastatic prostate cancer, sarcoma, and pancreas cancer preclinical models. Target for Phase I clinical study early 2027. Developed for partnering and licensing to biopharma.

8MQI-181 (pH-Sensitive ADC)
CategoryProprietary Preclinical Candidate
Description

pH-sensitive Antibody Drug Conjugate for hemato-oncology. Novel tumor-specific immunotherapy designed for lymphoma and blood cancers, targeting the tumor microenvironment with potential to evolve into next-generation ADC format. Currently in preclinical stage with in-vivo data available, open for partnering.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Syndivia
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-09
Description

Mabqi and Syndivia entered a research collaboration in 2023 to discover and develop a new ADC drug candidate with indications in prostate cancer. Mabqi's LiteMab Antibody Discovery Studio identified the antibody, which was then tailored to meet precise functional requirements including affinity, developability, and pharmacological properties. Syndivia designed the final ADC candidate and conducted full preclinical characterization using its GeminiMab ADC platform. Syndivia exercised an option on the jointly discovered DAR1 ADC, which was subsequently acquired by a leading pharmaceutical company in January 2026.

mabqi.com
2IOME Bio
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-07
Description

Mabqi co-authored a scientific publication with IOME Bio on the discovery and preclinical characterization of potent anti-RGMb antibodies blocking multiple ligand bindings, published in mAbs (2024). IOME Bio led the research project focused on the Repulsive Guidance Molecule b (RGMb) co-inhibitory pathway in T cells for anti-tumor immunity enhancement.

genengnews.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-06
Description

Mabqi and Abzena established a strategic partnership integrating Mabqi's LiteMab Antibody Discovery Studio with Abzena's development and manufacturing capabilities to offer biopharma customers a streamlined end-to-end drug development solution. The collaboration leverages Mabqi's hit screening, characterization, and lead selection using universal and pH-sensitive libraries, combined with Abzena's capabilities for developability, cell line development, process development, and GMP manufacturing. Both organizations support a broad range of modalities including monoclonal antibodies, mAb fragments, bispecifics, multispecifics, and bioconjugates.

4Paris Saclay Cancer Cluster (PSCC)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-25
Description

Mabqi joined PSCC Connect, the Paris-Saclay Cancer Cluster network. PSCC is a world-class innovation hub dedicated to accelerating cancer research, therapy development, and patient care by bringing together academic institutions, hospitals, and biotech companies. Mabqi was subsequently selected for the PSCC BOOST Programme, providing tailored scientific and medical support, access to expert ecosystem, hospital networks, industry partners, and investors to accelerate development of its lead asset toward clinical stages.

mabqi.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

SATT Nord (Société d'Accélération du Transfert de Technologies) collaborated with Mabqi and INSERM teams in Lille on the discovery and characterization of the first-in-class MQI-201 anti-TRPV6 antibody. SATT Nord manages technology transfer for research institutions in Northern France.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

INSERM research teams in Lille collaborated with Mabqi on the discovery of the MQI-201 anti-TRPV6 antibody. The academic partnership contributed scientific expertise in ion channel biology and oncology research, resulting in a first-in-class therapeutic antibody candidate with demonstrated efficacy in prostate cancer models.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Mabqi was selected for the France 2030 Export program, a strategic initiative supporting France's most innovative companies in international expansion. The program provides high-impact export support including global visibility, targeted international missions, and strategic expertise. Business France, the French government agency for international development, manages the program.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Adimab operates a yeast display-based antibody discovery platform serving biopharma partners with fully human antibody leads—directly comparable to Mabqi's LiteMab platform in technology, B2B service model, and target customer base.

TypeDirect peer
Description

AbCellera is an AI-powered antibody discovery company combining immune repertoire sequencing with high-throughput screening—comparable to Mabqi's AI-powered dual display platform in tech approach and biopharma service offering.

3Yumab
TypeDirect peer
Description

Yumab is a German antibody discovery CRO offering fully human antibody generation via in silico and phage display technologies—a similarly sized European peer with overlapping service offerings and customer base.

TypeDirect peer
Description

Trianni provides transgenic human antibody platform technology (Trianni Mouse) for fully human antibody discovery—comparable to Mabqi's synthetic library approach in delivering IP-clean, fully human antibodies to biopharma partners.

TypeDirect peer
Description

AbTherx is an antibody platform company with proprietary transgenic and AI-enabled discovery technologies—competes with Mabqi in the antibody discovery services market with a similar technology-driven value proposition.

TypeDirect peer
Description

Specifica is an antibody discovery company specializing in next-generation phage display libraries—a directly comparable platform peer offering antibody library-based discovery services to biopharma partners.

TypeDirect peer
Description

Numab is a Swiss biotech developing multispecific antibody therapeutics using a proprietary antibody fragment platform—comparable to Mabqi in European origin, antibody platform technology, and therapeutic pipeline focus in oncology.

8Harbour BioMed
TypeDirect peer
Description

Harbour BioMed operates a transgenic animal-based antibody discovery platform (Harbour Mice) for fully human antibody generation—a comparable platform peer in antibody technology and biopharma partnership model.

TypeBroad incumbent
Description

MorphoSys (acquired by Novartis in 2024) is a larger established antibody therapeutics company with proprietary antibody libraries and multiple approved/clinical assets—a broader incumbent operating in Mabqi's therapeutic space.

TypeBroad incumbent
Description

WuXi Biologics is a global contract development and manufacturing organization offering end-to-end biologics services including antibody discovery, development, and manufacturing—a broad incumbent serving Mabqi's customer base with integrated offerings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mabqi

Biopharmaceutical R&D Servicesmabqi.com

Mabqi firmographics

Firmographics
Name
Mabqi
Legal name
MABQI S.A.S.
Website
https://mabqi.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Mabqi industry classification

Industry
Product category
Biopharmaceutical R&D Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Pharmaceutical Preparation Manufacturing (325412)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Antibody discovery services
  • Therapeutic antibody development
  • Phage display technology
  • Oncology biopharmaceuticals
  • Antibody drug conjugates

Where Mabqi is headquartered

Location

Headquarters

HQ city
Grabels
HQ country
France
HQ region
Europe

Offices3 records

Markets served

Mabqi business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Partnership and Collaborative Research Agreements: Mabqi generates revenue through fee-for-service discovery partnerships with biopharma companies, where it applies its LiteMab platform to discover antibodies against targets defined by partners. Revenue is earned at project milestones (hit identification, lead selection, IND-enabling studies).
  2. Licensing and Milestone Payments: The company earns licensing revenue and milestone payments when partnered antibody programs advance through development and regulatory stages. The Syndivia ADC licensing agreement (January 2026) exemplifies this model, where an option on a jointly discovered ADC was exercised by a pharma company, generating licensing income.
  3. Non-Dilutive Public Funding: Mabqi supplements its operations through non-dilutive public funding grants, notably the €5 million France 2030 award in 2025 to advance lead candidate MQI-201. This supports preclinical development and IND-enabling studies without equity dilution.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Mabqi product offering

Product offering

Core offering

Mabqi is a biopharmaceutical company that discovers and develops next-generation therapeutic antibodies and immunotherapies, primarily in oncology. The company operates the LiteMab© Antibody Discovery Studio, an integrated platform combining proprietary fully human synthetic antibody libraries (HuscI2 and pHuscI2) with AI-powered phage and yeast display technologies to deliver developable therapeutic antibody candidates in approximately 4 months. Mabqi offers fee-for-service discovery partnerships, co-development collaborations, and licensing arrangements to biopharma clients, and is also advancing a proprietary pipeline including MQI-201 and MQI-181.

Product overview

Mabqi offers a unified antibody discovery ecosystem centered on the LiteMab© Antibody Discovery Studio, which integrates three core platforms: LiteMab© for conventional fully human antibody discovery from proprietary synthetic libraries; LiteMab© Sense for conditionally active pH-sensitive tumor-selective antibodies; and LiteMab© Neo for affinity maturation and LiteMab© Neo Sense for pH-sensitive maturation. The company leverages AI-powered phage and yeast display technologies to deliver readily developable therapeutic candidates across formats including conventional mAbs, bispecifics/multispecifics, T-cell engagers (TCEs), and antibody-drug conjugates (ADCs). Mabqi's proprietary pipeline includes MQI-201 (first-in-class anti-TRPV6 antibody for solid tumors, entering clinical development) and MQI-181 (pH-sensitive ADC for hemato-oncology), alongside multiple discovery-stage programs. Services include antibody characterization, developability assessment, and functional validation through internalization and cytotoxicity assays.

Differentiator

Problem solved

Functional benefit

Products and services

  • LiteMab© Antibody Discovery Studio Comprehensive integrated antibody discovery platform combining proprietary fully human synthetic libraries with AI-powered phage and yeast display technologies for high-throughput selection, screening, and functional validation of therapeutic antibody candidates. Supports conventional mAbs, bispecifics, multispecifics, T-cell engagers, pH-sensitive antibodies, and ADCs.
  • LiteMab© (Core Antibody Discovery) Core antibody discovery offering powered by proprietary high-diversity fully human synthetic antibody libraries spanning broad structural and paratope landscapes. Enables discovery of conventional antibodies including against complex and difficult targets such as GPCRs and ion channels.
  • LiteMab© Sense (pH-Sensitive Antibodies) Conditionally active pH-sensitive antibody discovery offering leveraging a proprietary fully human synthetic pH-sensitive naive library (pHuscI2). Generates tumor-selective antibodies that preferentially bind in the acidic tumor microenvironment while showing reduced binding at physiological pH, enhancing specificity and reducing off-tumor toxicity.
  • LiteMab© Neo (Affinity Maturation) Affinity maturation platform for next-generation biologics. Provides customized library design based on parental sequences with AI-powered dual display technology enabling precise tuning of affinity, pH sensitivity, and functional activity while preserving developability.
  • Antibody Drug Conjugate (ADC) Discovery ADC discovery service combining targeting specificity of monoclonal antibodies with potent cytotoxicity of chemotherapeutic agents. Supports generation of native or pH-sensitive antibodies using AI-powered dual display for rapid clone identification, hit characterization, and functional validation including internalization assays and cytotoxicity testing.
  • Bispecific & Multispecific Antibody Discovery Discovery service delivering high-affinity binders tailored for complex bispecific, multispecific, and T-cell engager (TCE) formats. Leverages AI-powered dual-display workflows and synthetic libraries with scFv format enabling rapid assembly and flexible combination of binding domains.
  • MQI-201 (Anti-TRPV6 Antibody Candidate) First-in-class anti-TRPV6 antibody therapeutic candidate for solid tumors. Demonstrated safety and efficacy in metastatic prostate cancer, sarcoma, and pancreas cancer preclinical models. Target for Phase I clinical study early 2027. Developed for partnering and licensing to biopharma.
  • MQI-181 (pH-Sensitive ADC) pH-sensitive Antibody Drug Conjugate for hemato-oncology. Novel tumor-specific immunotherapy designed for lymphoma and blood cancers, targeting the tumor microenvironment with potential to evolve into next-generation ADC format. Currently in preclinical stage with in-vivo data available, open for partnering.

Quantifiable outcome

  • 4-month timeline from target to validated lead
  • +3 more outcomes

Companies that use Mabqi

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Mabqi technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Mabqi partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, minor and major.

  • SyndiviacoreStrategic or Co-development Partner · 9 January 2026Mabqi and Syndivia entered a research collaboration in 2023 to discover and develop a new ADC drug candidate with indications in prostate cancer. Mabqi's LiteMab Antibody Discovery Studio identified the antibody, which was then tailored to meet precise functional requirements including affinity, developability, and pharmacological properties. Syndivia designed the final ADC candidate and conducted full preclinical characterization using its GeminiMab ADC platform. Syndivia exercised an option on the jointly discovered DAR1 ADC, which was subsequently acquired by a leading pharmaceutical company in January 2026.
  • IOME BiominorStrategic or Co-development Partner · 7 November 2025Mabqi co-authored a scientific publication with IOME Bio on the discovery and preclinical characterization of potent anti-RGMb antibodies blocking multiple ligand bindings, published in mAbs (2024). IOME Bio led the research project focused on the Repulsive Guidance Molecule b (RGMb) co-inhibitory pathway in T cells for anti-tumor immunity enhancement.
  • AbzenacoreStrategic or Co-development Partner · 6 November 2025Mabqi and Abzena established a strategic partnership integrating Mabqi's LiteMab Antibody Discovery Studio with Abzena's development and manufacturing capabilities to offer biopharma customers a streamlined end-to-end drug development solution. The collaboration leverages Mabqi's hit screening, characterization, and lead selection using universal and pH-sensitive libraries, combined with Abzena's capabilities for developability, cell line development, process development, and GMP manufacturing. Both organizations support a broad range of modalities including monoclonal antibodies, mAb fragments, bispecifics, multispecifics, and bioconjugates.
  • Paris Saclay Cancer Cluster (PSCC)coreStrategic or Co-development Partner · 25 August 2025Mabqi joined PSCC Connect, the Paris-Saclay Cancer Cluster network. PSCC is a world-class innovation hub dedicated to accelerating cancer research, therapy development, and patient care by bringing together academic institutions, hospitals, and biotech companies. Mabqi was subsequently selected for the PSCC BOOST Programme, providing tailored scientific and medical support, access to expert ecosystem, hospital networks, industry partners, and investors to accelerate development of its lead asset toward clinical stages.
  • SATT NordmajorStrategic or Co-development PartnerSATT Nord (Société d'Accélération du Transfert de Technologies) collaborated with Mabqi and INSERM teams in Lille on the discovery and characterization of the first-in-class MQI-201 anti-TRPV6 antibody. SATT Nord manages technology transfer for research institutions in Northern France.
  • INSERM (Lille)majorStrategic or Co-development PartnerINSERM research teams in Lille collaborated with Mabqi on the discovery of the MQI-201 anti-TRPV6 antibody. The academic partnership contributed scientific expertise in ion channel biology and oncology research, resulting in a first-in-class therapeutic antibody candidate with demonstrated efficacy in prostate cancer models.
  • Business France (France 2030 Export Program)minorGTM or Marketing PartnerMabqi was selected for the France 2030 Export program, a strategic initiative supporting France's most innovative companies in international expansion. The program provides high-impact export support including global visibility, targeted international missions, and strategic expertise. Business France, the French government agency for international development, manages the program.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Mabqi competitors and assessment

Company assessment

Direct peers

  • Adimab: Adimab operates a yeast display-based antibody discovery platform serving biopharma partners with fully human antibody leads—directly comparable to Mabqi's LiteMab platform in technology, B2B service model, and target customer base.
  • AbCellera: AbCellera is an AI-powered antibody discovery company combining immune repertoire sequencing with high-throughput screening—comparable to Mabqi's AI-powered dual display platform in tech approach and biopharma service offering.
  • Yumab: Yumab is a German antibody discovery CRO offering fully human antibody generation via in silico and phage display technologies—a similarly sized European peer with overlapping service offerings and customer base.
  • Trianni: Trianni provides transgenic human antibody platform technology (Trianni Mouse) for fully human antibody discovery—comparable to Mabqi's synthetic library approach in delivering IP-clean, fully human antibodies to biopharma partners.
  • AbTherx: AbTherx is an antibody platform company with proprietary transgenic and AI-enabled discovery technologies—competes with Mabqi in the antibody discovery services market with a similar technology-driven value proposition.
  • Specifica: Specifica is an antibody discovery company specializing in next-generation phage display libraries—a directly comparable platform peer offering antibody library-based discovery services to biopharma partners.
  • Numab Therapeutics: Numab is a Swiss biotech developing multispecific antibody therapeutics using a proprietary antibody fragment platform—comparable to Mabqi in European origin, antibody platform technology, and therapeutic pipeline focus in oncology.
  • Harbour BioMed: Harbour BioMed operates a transgenic animal-based antibody discovery platform (Harbour Mice) for fully human antibody generation—a comparable platform peer in antibody technology and biopharma partnership model.

Broad incumbents

  • MorphoSys (Novartis): MorphoSys (acquired by Novartis in 2024) is a larger established antibody therapeutics company with proprietary antibody libraries and multiple approved/clinical assets—a broader incumbent operating in Mabqi's therapeutic space.
  • WuXi Biologics: WuXi Biologics is a global contract development and manufacturing organization offering end-to-end biologics services including antibody discovery, development, and manufacturing—a broad incumbent serving Mabqi's customer base with integrated offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Mabqi social profiles

Digital presence

Mabqi financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mabqi leadership team

Management profile

Number of profiles

Profiles12 records

Mabqi funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mabqi M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mabqi

What does Mabqi do?

Mabqi is a biopharmaceutical company that discovers and develops next-generation therapeutic antibodies and immunotherapies, primarily in oncology. The company operates the LiteMab© Antibody Discovery Studio, an integrated platform combining proprietary fully human synthetic antibody libraries (HuscI2 and pHuscI2) with AI-powered phage and yeast display technologies to deliver developable therapeutic antibody candidates in approximately 4 months. Mabqi offers fee-for-service discovery partnerships, co-development collaborations, and licensing arrangements to biopharma clients, and is also advancing a proprietary pipeline including MQI-201 and MQI-181.

Is Mabqi a public or private company?

Mabqi is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Mabqi founded?

Mabqi was founded in 2017. It employs 11 to 50 people.

Where is Mabqi based?

Mabqi is headquartered in Grabels, France, in the Europe region.

How does Mabqi make money?

Three revenue lines are on record. Partnership and Collaborative Research Agreements are the primary driver. The others are licensing and Milestone Payments and non-Dilutive Public Funding.

Who are Mabqi's main competitors?

Direct peers on record are Adimab, AbCellera, Yumab, Trianni, AbTherx, Specifica, Numab Therapeutics and Harbour BioMed. Broad incumbents are MorphoSys (Novartis) and WuXi Biologics.

Does Mabqi have an API?

No public API is recorded for Mabqi.

What industry is Mabqi in?

Mabqi's product category is Biopharmaceutical R&D Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals